Clopidogrel Tablet, Film Coated
Product Images NDC 82804-986

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 82804-986). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel 01)

Chemical structure of Clopidogrel Bisulfate showing the molecular arrangement including a thiophene ring, methyl ester group, chlorine-substituted phenyl ring, and sulfate salt component (H2SO4).*

FDA Label Image

Figure 1 (Clopidogrel 02)

A horizontal error bar chart comparing four proton pump inhibitors: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. Each drug is plotted on the vertical axis with a corresponding horizontal bar representing a measured value ranging approximately from 0.4 to 1.4, with a vertical reference line at 1.0 on the horizontal axis.*

FDA Label Image

Figure 2 (Clopidogrel 03)

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two groups are compared: placebo (+ aspirin) and clopidogrel (+ aspirin), with clopidogrel showing a lower cumulative event rate. A p-value of 0.00009 is noted, indicating statistical significance.*

FDA Label Image

Figure 3 (Clopidogrel 04)

A forest plot chart depicting hazard ratios with 95% confidence intervals comparing Clopidogrel and placebo across various subgroups including age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke. The chart shows the number of subjects and event percentages for each treatment group, indicating which treatment is favored per subgroup.*

FDA Label Image

Figure 3 (Clopidogrel 05)

A forest plot chart comparing subgroups of patients treated with Clopidogrel versus placebo across various co-therapies like Heparin/LMWH, Aspirin dosages, GPIIb/IIIa antagonist, Beta-Blocker, and ACE inhibitor. The chart visually presents hazard ratios with 95% confidence intervals, indicating the relative favorability between Clopidogrel and placebo treatments for each subgroup and overall population.*

FDA Label Image

Figure 4 (Clopidogrel 06)

A line chart showing the percentage of deaths before first discharge over 28 days since randomization, comparing Clopidogrel versus placebo. The graph indicates cumulative deaths with Clopidogrel showing 7.5% deaths (1726 deaths) and placebo showing 8.1% deaths (1845 deaths), with a 7% proportional risk reduction (p=0.03) in the Clopidogrel group.*

FDA Label Image

Figure 5 (Clopidogrel 07)

A clinical trial event rate graph showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days. It compares Clopidogrel with placebo, noting 9.2% vs. 10.1% event rates respectively, including a 9% proportional risk reduction for Clopidogrel (p=0.002). The x-axis shows days since randomization up to 28 days and the y-axis shows the percentage of patients with events.*

FDA Label Image

Figure 6 (Clopidogrel 08)

A forest plot displaying odds ratios with 99% confidence intervals comparing the effects of Clopidogrel versus placebo across various subgroups including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The overall summary is shown at the bottom, indicating the comparative odds ratio between Clopidogrel and placebo.*

FDA Label Image

Figure 7 (Clopidogrel 09)

A line graph depicting the cumulative event rate (%) of fatal or non-fatal vascular events over months of follow-up (0 to 36 months) for aspirin and clopidogrel. The graph shows two lines with clopidogrel slightly lower than aspirin, and a p-value of 0.045 indicating statistical analysis of the difference between the groups.*

FDA Label Image

Figure 8 (Clopidogrel 10)

A forest plot displaying hazard ratios with 95% confidence intervals comparing Clopidogrel and Aspirin across qualifying conditions: Stroke, MI, PAD, and Overall. The x-axis represents hazard ratios from 0.6 to 1.3, indicating which treatment each condition favors based on the plotted diamonds and lines.*

FDA Label Image

82804-986-30 (Clopidogrel 11)

Label for Clopidogrel 300 mg tablets by Proficient Rx LP, containing 30 film-coated tablets. Each tablet has 391.5 mg clopidogrel bisulfate equivalent to 300 mg clopidogrel base. Tablets are pink, modified oval, debossed with SG and 121. Manufactured by ScieGen Pharmaceuticals, Inc., Hauppauge, NY.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.